Regencell Bioscience Holdings Limited is a clinical-stage bioscience company that aims to bridge Traditional Chinese Medicine (TCM) with modern drug development. Founded in 2014 and headquartered in Hong Kong, the company is primarily focused on developing standardized TCM formulations for the treatment of neurocognitive and neurodevelopmental disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Additionally, Regencell investigates TCM treatments for infectious diseases that affect the immune system, such as COVID-19. The company's therapeutic candidates are derived from proprietary TCM base formulas and adjustable formulas developed by its partnering TCM practitioner. As an early-stage pharmaceutical firm, Regencell is currently pre-revenue (as confirmed by its fiscal year 2024 SEC filings) and does not generate operating income, funding its operations and clinical trials through equity financing and capital markets. The company conducts its research and clinical studies primarily in Hong Kong, with plans to commercialize its liquid-based standardized TCM formulas initially in the local market before expanding globally. Regencell operates as a holding company, conducting its core research and development activities through its wholly-owned subsidiaries.
